Compounds > abiraterone
Page last updated: 2024-09-04

abiraterone and Cardiac Failure

abiraterone has been researched along with Cardiac Failure in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Bretagne, M; Dureau, P; Funck-Brentano, C; Lebrun-Vignes, B; Malouf, GG; Moslehi, JJ; Pariente, A; Potey, C; Roden, DM; Salem, JE; Shaffer, CM1
Addison, D; Baumann, BC; Calaway, AC; Campbell, CM; Cullen, J; Desai, NR; Fradley, MG; Garcia, JA; Ghosh, AK; Guha, A; Lenihan, DJ; Ponsky, L; Reimers, MA; Weintraub, N; Zhang, KW1
Akise, Y; Endo, J; Itabashi, Y; Kageyama, T; Mitamura, H; Murata, M; Nagatomo, Y; Nakajima, Y; Tsugu, T1

Other Studies

3 other study(ies) available for abiraterone and Cardiac Failure

ArticleYear
Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
    Archives of cardiovascular diseases, 2020, Volume: 113, Issue:1

    Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Cardiotoxicity; Databases, Factual; Heart Failure; Humans; Male; Middle Aged; Nitriles; Pharmacovigilance; Phenylthiohydantoin; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Tachycardia, Supraventricular; Time Factors

2020
Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
    The Journal of urology, 2021, Volume: 206, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Databases, Factual; Gonadotropin-Releasing Hormone; Heart Failure; Humans; Hypertension; Male; Middle Aged; Pharmacovigilance; Prostatic Neoplasms; Retrospective Studies; United States; United States Food and Drug Administration; Young Adult

2021
Cancer therapeutics-related cardiac dysfunction in a patient treated with abiraterone for castration-resistant prostate cancer.
    Journal of medical ultrasonics (2001), 2019, Volume: 46, Issue:2

    Topics: Aged, 80 and over; Androstenes; Antineoplastic Agents; Disease Progression; Drug Substitution; Heart Failure; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2019